Immune rejection: the immune biology of allogeneic hematopoietic stem cell transplantation (from mice to humans) - Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - page 119

[130] Milstein O, Hagin D, Lask A, Reich-Zeliger S, Shezen E, Ophir E, et al. CTLs respond
with activation and granule secretion when serving as targets for T-cell recognition.
Blood 2011;117:1042-52.
[131] Azuma E, Yamamoto H, Kaplan J. Use of lymphokine-activated killer cells to prevent bone
marrow graft rejection and lethal graft-vs-host disease. J Immunol 1989;143:1524-9.
[132] Murphy WJ, Bennett M, Kumar V, Longo DL. Donor-type activated natural killer cells
promote marrow engraftment and B cell development during allogeneic bone marrow
transplantation. J Immunol 1992;148:2953-60.
[133] Reich-Zeliger S, Bachar-Lustig E, Gan J, Reisner Y. Tolerance induction by veto CTLs in
the TCR transgenic 2C mouse model. I. Relative reactivity of different veto cells. J Im-
munol 2004;173:6654-9.
[134] Taylor PA, Ehrhardt MJ, Lees CJ, Panoskaltsis-Mortari A, Krieg AM, Sharpe AH, et al.
TLR agonists regulate alloresponses and uncover a critical role for donor APCs in al-
logeneic bone marrow rejection. Blood 2008;112:3508-16.
[135] Hu B, He Y, Wu Y, Bao G, Liu H, Welniak LA, et al. Activated allogeneic NK cells as sup-
pressors of alloreactive responses. Biol Blood Marrow Transplant 2010;16:772-81.
[136] Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effective-
ness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.
Science 2002;295:2097-100.
[137] Bishara A, De Santis D, Witt CC, Brautbar C, Christiansen FT, Or R, et al. The beneficial
role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched
stem cell allografts may be masked by residual donor-alloreactive T cells causing
GVHD. Tissue Antigens 2004;63:204-11.
[138] Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JS, et al. Evaluation of
KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants.
Killer immunoglobulin-like receptor. Blood 2002;100:3825-7.
[139] Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caligiuri MA, et al. The effect of
KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report
from the center for international blood and marrow transplant research, the European
blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Trans-
plant 2006;12:876-84.
[140] Kaufman CL, Colson YL, Wren SM, Watkins S, Simmons RL, Ildstad ST. Phenotypic
characterization of a novel bone marrow-derived cell that facilitates engraftment of
allogeneic bone marrow stem cells. Blood 1994;84:2436-46.
[141] Gandy KL, Domen J, Aguila H, Weissman IL. CD8 + TCR + and CD8 + TCR-cells in whole
bone marrow facilitate the engraftment of hematopoietic stem cells across allogeneic
barriers. Immunity 1999;11:579-90.
[142] Strober S, Hertel-Wulff B, Schwadron RB. Role of natural suppressor cells in bone mar-
row transplantation. Transplant Proc 1987;19:88-94.
[143] Taylor KN, Shinde-Patil VR, Cohick E, Colson YL. Induction of FoxP3 + CD4 + 25 + regulato-
ry T cells following hemopoietic stem cell transplantation: role of bone marrow-derived
facilitating cells. J Immunol 2007;179:2153-62.
[144] Huang Y, Bozulic LD, Miller T, Xu H, Hussain LR, Ildstad ST. CD8α + plasmacytoid pre-
cursor DCs induce antigen-specific regulatory T cells that enhance HSC engraftment
in vivo . Blood 2011;117:2494-505.
[145] Urbieta M, Barao I, Jones M, Jurecic R, Panoskaltsis-Mortari A, Blazar BR, et al. Hemato-
poietic progenitor cell regulation by CD4 + CD25 + T cells. Blood 2010;115:4934-43.
[146] Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell
2000;101:455-8.
[147] Nguyen VH, Zeiser R, Negrin RS. Role of naturally arising regulatory T cells in hemato-
poietic cell transplantation. Biol Blood Marrow Transplant 2006;12:995-1009.
[148] Taylor PA, Panoskaltsis-Mortari A, Swedin JM, Lucas PJ, Gress RE, Levine BL, et al.
L-Selectin(hi) but not the L-selectin(lo) CD4 + 25 + T-regulatory cells are potent inhibitors
of GVHD and BM graft rejection. Blood 2004;104:3804-12.
[149] Hanash AM, Levy RB. Donor CD4 + CD25 + T cells promote engraftment and tolerance fol-
lowing MHC-mismatched hematopoietic cell transplantation. Blood 2005;105:1828-36.
[150] Barao I, Hanash AM, Hallett W, Welniak LA, Sun K, Redelman D, et al. Suppression of
natural killer cell-mediated bone marrow cell rejection by CD4 + CD25 + regulatory T
cells. Proc Natl Acad Sci USA 2006;103:5460-5.
[151] Joffre O, Santolaria T, Calise D, Al Saati T, Hudrisier D, Romagnoli P, et al. Prevention of
acute and chronic allograft rejection with CD4 + CD25 + Foxp3 + regulatory T lymphocytes.
Nat Med 2008;14:88-92.
[152] Shatry A, Levy RB. In situ activation and expansion of host tregs: a new approach
to enhance donor chimerism and stable engraftment in major histocompatibility
complex-matched allogeneic hematopoietic cell transplantation. Biol Blood Marrow
Transplant 2009;15:785-94.

121